Amgen (AMGN): The Biotech Pioneer Preparing for Its Next Growth Wave

• Amgen pioneered biotech by replicating complex biomolecules like proteins and hormones, not just chemicals • Founded 1980, built blockbusters EPOGEN, NEUPOGEN, then grew via acquisitions (Immunex, Horizon) • 2025 revenue $36.8B, net income $11.8B; now entering obesity market with MariTide Pharmaceuticals began with purifying natural compounds, then synthesizing new chemicals. But some diseases require replicating large biomolecules like DNA, proteins, and hormones instead of chemicals — this became biotechnology. Amgen, founded in 1980, was central to building this industry. After insulin pioneer Genentech partnered with Eli Lilly (LLY) for recombinant insulin, Amgen pivoted its R&D and IPO'd in 1983, developing Epoetin alfa/EPOGEN (anemia) and Filgrastim/NEUPOGEN (cancer infections) — blockbusters that generated over $1B combined by 1992. Amgen expanded manufacturing globally (Puerto Rico, Netherlands, Ireland, Singapore, Brazil) and grew its pipeline through acquisitions: Immunex ($16B, 2000s) for inflammatory drugs, Otezla (2019) for immunology, and Horizon Therapeutics ($27.8B, 2023) for rare diseases. It's now entering the obesity market with MariTide, whose less-frequent dosing could rival Ozempic and Mounjaro. Amgen (AMGN) employs 31,500 people and self-manufactures most products. In 2025, it generated $36.8B in revenue, $11.8B net income, and $8.1B free cash flow, with seven drugs exceeding $1B each, led by Prolia & XGEVA ($6.6B) and Repatha ($3.0B, up 37%). Its portfolio spans rare diseases, oncology, inflammation, and general medicine.